Evidence that lithium protects against tardive dyskinesia: The Curacao Extrapyramidal Syndromes study VI

Peter N. van Harten*, Hans W. Hoek, Glenn E. Matroos, Jim van Os

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    14 Citations (Scopus)

    Abstract

    Lithium may have neuroprotective properties and therefore could affect the occurrence of tardive dyskinesia (TD). We conducted a nine-year follow-up study with one baseline and six follow-up assessments including all psychiatric inpatients in Curacao (N = 194). TD was measured with the Abnormal Involuntary Movement Rating Scale (AIMS). There were 758 follow-up observations in the 166 patients (mean age 54.4 yrs, SD 16.0) with at least one follow-up assessment. Most patients (74%) had schizophrenia. The mean baseline score of the AIMS was 4.1 (SD 4.7). Sixteen patients (9.6%) used lithium at baseline and eight patients started lithium during follow-up. Prevalent and incident lithium significantly reduced the severity of existing TD with respectively 2.3 and 2.9 point reduction on the AIMS (AIMS score range: 0-23) and a standardised effect size of 0.5 for prevalent TD and 0.6 for incident TD. In the restricted sample of those with a baseline score of zero on the AIMS, prevalent lithium significantly towered the risk of new abnormal movements (standardised effect size of 0.7). In conclusion, the use of lithium was significantly negatively associated with both persistence and onset of TD. These results suggest a beneficial effect on TD of lithium in some patients using long-term antipsychotics. (C) 2007 Elsevier B.V. and ECNP. All rights reserved.

    Original languageEnglish
    Pages (from-to)152-155
    Number of pages4
    JournalEuropean Neuropsychopharmacology
    Volume18
    Issue number2
    DOIs
    Publication statusPublished - Feb-2008

    Keywords

    • tardive dyskinesia
    • incidence
    • course
    • lithium
    • neuroprotective
    • follow-up study
    • RISK-FACTORS
    • HUMAN BRAIN
    • PATHOPHYSIOLOGY
    • ANTIPSYCHOTICS
    • SCHIZOPHRENIA
    • OUTPATIENTS
    • PREVALENCE
    • DYSTONIA
    • DRUGS

    Cite this